Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from $54.00 to $59.00 in a note issued to investors on Tuesday, BayStreet.CA reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective points to a […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) and ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Analyst Ratings This is a breakdown of current […]
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Risk and Volatility Xenon Pharmaceuticals has a beta […]